🇺🇸 FDA
Pipeline program

LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten

BO45853

Phase 2 small_molecule active

Quick answer

LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten for Early-Stage, PIK3CA-Mutated Breast Cancer (BC) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Early-Stage, PIK3CA-Mutated Breast Cancer (BC)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials